Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 1;23(1):6-8.
doi: 10.1158/1078-0432.CCR-16-2400. Epub 2016 Nov 1.

Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk

Yu Yin  1   2 , Qingfu Zhang  2   3 , Hong Zhang  2 , Yiping He  2 , Jiaoti Huang  4
Affiliations

Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk

Yu Yin et al. Clin Cancer Res. .

Abstract

A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6-8. ©2016 AACRSee related article by Sinnott et al., p. 81.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Integration of clinical, pathological, radiological and molecular tools for the management of patients with suspected and confirmed prostate cancer.
See this image and copyright information in PMC

Comment on

References

    1. Sinnott JAPS, Tyekucheva S, Gerke T, Lis R, Rider JR, et al. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clinical Cancer Research. 2016 (Current Issue) - PMC - PubMed
    1. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(17):2391–6. doi: 10.1200/jco.2010.32.6421. - DOI - PMC - PubMed
    1. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. European urology. 2012;62(6):976–83. doi: 10.1016/j.eururo.2012.05.072. - DOI - PubMed
    1. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(2):228–34. doi: 10.1200/jco.2010.31.4252. - DOI - PMC - PubMed
    1. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. The Journal of urology. 2013;190(6):2047–53. doi: 10.1016/j.juro.2013.06.017. - DOI - PMC - PubMed